MLchartDataset catalogue

IMMU-110

Term · Oncology and biomedicine · MLC-T-ONC-004195

A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody. Also called hLL1 and milatuzumab.

Table 1. Record
IdentifierMLC-T-ONC-004195
FieldOncology and biomedicine
Expansionsmilatuzumab
SynonymshLL1
ReferencesNCI Dictionary of Cancer Terms
Record as JSON 
{
  "id": "MLC-T-ONC-004195",
  "term": "IMMU-110",
  "field": "Oncology and biomedicine",
  "definition": "A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody. Also called hLL1 and milatuzumab.",
  "expansions": [
    "milatuzumab"
  ],
  "synonyms": [
    "hLL1"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/immu-110/"
}

Record 9,066 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.